Tivozanib Improves PFS in Highly Refractory RCC
November 6th 2018The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.
Read More
Venetoclax Plus Obinutuzumab Improves PFS in Frontline CLL
November 1st 2018The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) reduced the risk of disease progression or death versus obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.
Read More
FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer
October 26th 2018The FDA has granted a priority review to a supplemental new drug application for TAS-102 for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
Read More